Q-omics provides the consensus-scored RN7SL850P profile across patient tissues and cancer cell-line models. RN7SL850P expression is associated with patient survival in 19 of 34 cancer types, with the highest sampling consensus in MESO. Among the 18 cancer types available for tumor–normal comparison, RN7SL850P is differentially expressed in 5, with the highest sampling consensus in BLCA. Additionally, RN7SL850P RNA expression shows 6,367 significant pathway-activity associations, with the highest sampling consensus in STAD. Together, these results highlight MESO, BLCA, and STAD as cancer lineages where RN7SL850P shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for RN7SL850P — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes RN7SL850P survival associations across molecular data types. RN7SL850P RNA expression shows survival associations in the most cancer types (19). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible RN7SL850P RNA expression–survival associations across cancer types. High RN7SL850P expression shows unfavorable associations in KIRC, UVM, KIRP and COAD, but favorable associations in MESO and SKCM. The MESO Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p = .004). Together, the overview and detailed table identify MESO as the clearest survival context for RN7SL850P RNA expression.
This table summarizes RN7SL850P tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 5. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for RN7SL850P. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. RN7SL850P shows lower tumor expression in COAD and higher tumor expression in BLCA, KIRC, STAD and KIRP. The BLCA box plot shows higher RN7SL850P RNA expression in tumor versus normal tissue (log2 FC = +0.178, t-test p = .008).
This table shows molecular features associated with RN7SL850P in patient tissues and cancer cell lines. In patient samples, RN7SL850P shows the broadest associations at the RNA and protein expression levels, with STAD recurring as the lineage with the largest associated feature set.
